During Part A, each patient will participate for up to 30 weeks, which includes a Screening Period of 1 to ≤ 6 weeks, followed by a Baseline Visit and 24 weeks of double-blind treatment:
* Screening Period: 1 - 6 weeks.
* Double-Blind Treatment Period: 24 weeks.
After completion of Part A, patients will continue in Part B for an additional 56 weeks:
* Open-Label Treatment Period: 52 weeks.
* Post-Treatment Safety Follow Up: 4 weeks.
